4ª Planta Pabellón B. Servicio de Neurología. Hospital Regional Universitario de Málaga
¿Quieres participar en un ensayo clínico? Haz click aquí
ENSAYOS PRÓXIMOS


MINT-C
LUCIA GARCIA
CEFALEA
FASE:
III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine


MINT-E
LUCIA GARCIA
CEFALEA
FASE:
III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine


NX-BRI-002
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
IV
Non-interventional, prospective, multicenter, European study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice


CATALPA
TERESA MUÑOZ
TRASTORNOS MOV.
FASE:
II
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants


CLOU064C12306
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
III
Efficacy and safety of remibrutinib after switching from ocrelizumab in people living with relapsing multiple sclerosis


PHENOALS-001
VIRGINIA REYES
NEUROMUSCULAR
FASE:
II
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi- Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS).


PRAX-628-212
PEDRO SERRANO
EPILEPSIA
FASE:
II
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures


M24-304
VIRGINIA REYES
NEUROMUSCULAR
FASE:
III
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Extension to Assess the Efficacy and Safety of Fosigotifator for the Treatment of Amyotrophic Lateral Sclerosis


Illuminate
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
ND
Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple


CLNP023Q12301
GUILLERMINA GARCIA
NEUROMUSCULAR
FASE:
III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase


Prasinezumab
LUCIA GARCIA
TRASTORNOS MOV.
FASE:
III
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early parkinson’s disease


NXPLEVE
PEDRO SERRANO
EPILEPSIA
FASE:
III
A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy


NVG-2089-201
GUILLERMINA GARCIA
NEUROMUSCULAR
FASE:
II
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)


LP352-301
PEDRO SERRANO
EPILEPSIA
FASE:
III
Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con encefalopatías epilépticas y del desarrollo


LP352-302
PEDRO SERRANO
EPILEPSIA
FASE:
III
Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con síndrome de Dravet


MN44358
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
IV
Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple


CLIN-10200-455
BEATRIZ FERNANDEZ
TRASTORNOS MOV.
FASE:
II
A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of Two Single Doses of IPN10200 for the Treatment of Blepharospasm in Adults


CVHB937B12201
VIRGINIA REYES
NEUROMUSCULAR
FASE:
II
Un estudio de fase 2 controlado con placebo de VHB937 en la esclerosis lateral amiotrófica (ELA) durante 40 semanas seguido de una extensión abierta


CLOU064O12301
VIRGINIA REYES
NEUROMUSCULAR
FASE:
III
Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad del remibrutinib en pacientes con miastenia grave generalizada seguido de una fase de extensión abierta


ARODM1-1001
VIRGINIA REYES
NEUROMUSCULAR
FASE:
I/II
Un estudio de fase 1/2a de escalamiento de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de aro-dm1 en sujetos con distrofia miotónica tipo 1 que tienen ≥18 a ≤65 años


67896153MSC3001
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
III
Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis


ABP 692
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
III
Un estudio de grupo paralelo, aleatorizado, doble ciego para comparar Farmacocinética, farmacodinamia, efectos clínicos y seguridad entre ABP 692 y Ocrevus (Ocrelizumab) en sujetos con esclerosis múltiple remitente recurrente.


MODERNA MS
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
II
A phase 2, randomized, observer-blind, placebo-controlled, dose-ranging study of mRNA-1195 intramuscular injection in participants 18 to ≤55 years of age with early MS


MAVENAGE
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
IV
A prospective observational study to evaluate the effectiveness and safety profile of cladribine tablets in a real-world cohort of relapsing multiple sclerosis patients older and younger than 50 years


COVIDGONITIVO
PEDRO SERRANO
DETERIORO COGNITIVO
FASE:
ND
Randomized placebo-controlled, double-blind clinical trial to investigate treatment effects and safety of Ginkgo biloba extract EGb 761® in participants with cognitive impairment associated with post-COVID-19 syndrome


IGM-2644-101
VIRGINIA REYES
NEUROMUSCULAR
FASE:
I
A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGM-2644 in Participants with Myasthenia Gravis


EFC18098
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
III
A randomized, phase III, open label study to investigate pharmacokinetics, safety, radiological and clinical effects of subcutaneous frexalimab (SAR441344) compared to intravenous frexalimab in adult participants with multiple sclerosis.


CYTB323R12101
ANA ALONSO
ESCLEROSIS MULTIPLE
FASE:
I/II
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with progressive Multiple Sclerosis (PMS)


AR1001-ADP3-US01
PEDRO SERRANO
ALZHEIMER
FASE:
III
Phase III Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s.


ARGX-113-2315
VIRGINIA REYES
NEUROMUSCULAR
FASE:
III
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis


ARGX-113-2308
VIRGINIA REYES
NEUROMUSCULAR
FASE:
III
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).
